March 10, 2023
EPS Holdings, Inc.
Logos Science Co., Ltd.
News Release

Notice Regarding Capital Alliance Between EPS Holdings, Inc. and Logos
Science Co., Ltd. as Strategic Partners
EPS Holdings, Inc. (Head Office: Shinjuku-ku, Tokyo; Representative Director: Hao YAN;
hereinafter “EPSHD”) hereby announces that it has entered into a capital alliance with Logos
Science Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director: Hideki TANEMURA;
hereinafter “Logos Science”) as a strategic partner for the purpose of jointly promoting theprovision of solution services in the area of mental health.

1. Purpose of Capital Alliance
EPSHD has been operating an outsourcing business for pharmaceutical and medical device
development with CRO*1, SMO*2, and CSO*3 at its core. The company conducted a managementbuyout (MBO) in 2021, and is expanding its activities into new areas with the aim of becoming asolution company for the entire healthcare industry that transcends conventional boundaries.
Logos Science was founded in 2022 by Ig Nobel laureate Hideki Tanemura with the aim ofproviding new solution services in the area of mental health. Currently, based on joint research withthe Institute of Applied Brain Sciences at Comprehensive Research Organization of Waseda
University, Logos Science is working on the development of a mental health self-care application“Dr. App®” *4 that supports the resolution of problems and difficulties associated with stress-relateddisorders.
In the clinical study to verify the feasibility of practical application, “Dr. App®” was evaluatedfor its usability and safety, and obtained favorable results, including significant improvements inoutcome measures.
EPSHD and Logos Science will not only form a capital alliance, but will also work as strategic
partners to combine EPSHD's knowledge in the healthcare field cultivated through its
pharmaceutical and medical device development business with the psychotherapy program which isthe base of Logos Science's “Dr. App®.” Through these efforts, the two companies will contributesolving social issues by developing self-care applications in the mental health field, building1evidence for such applications, and promoting marketing activities to develop new solution services
in the mental health field that have never existed before.
2. Details
In recent years, there have seen an increase in the number of patients with mental illnesses, with apatient survey conducted by the Ministry of Health, Labour and Welfare in 2017, that showing
approximately 4.2 million people affected by mental illnesses. Of these, depression, a stress-relatedillness, accounted for the largest number at 1.27 million. In particular, suicides among youngpeople, declining labor productivity due to presenteeism in companies, and the spread of ambiguous
anxiety in the recent COVID-19 pandemic have become social problems.
The Ministry of Health, Labour and Welfare is emphasizing the importance of early detection andprevention of stress-related illnesses through stress checks and other mental health measures in theworkplace and measures to prevent overwork. However, awareness of specific prevention measuresand self-care methods is not widespread.
Dr. App®, which is currently being developed by Logos Science in collaboration with theInstitute of Applied Brain Sciences at Comprehensive Research Organization of Waseda University,
replicates cognitive behavioral therapy and other psychotherapies, including Acceptance andCommitment Therapy (ACT), which are conducted by professionals in clinical psychology settings,
in an app program. The feasibility of its practical application was confirmed in a clinical study(feasibility study).
By developing a mental health self-care application that combines such psychotherapy programs
based on Logos Science's "Dr. App® " with EPSHD's knowledge in the healthcare domain
cultivated through its pharmaceutical and medical device development business to provide
companies and individuals with a measure of early detection of mental health problems and aquality self-care method, we expect that we can lead the way to the prevention of mental healthproblems.
EPSHD and Logos Science will work together to bring a mental health self-care application
within 2023 especially for companies and workers with the aim of practical use.
Through synergy between the new initiatives of the EPS Group, which is leaping into a new stage
as a solution provider 30 years after its establishment, and the initiatives of Logos ScienceCorporation, which is taking on the challenge of research and development to provide new solution
services in the area of mental health, we aim to create value which leads to social innovation.
3. Content of Capital Alliance
2EPSHD will acquire [90,000] shares of common stock issued by Logos Science for the purposeof promoting joint business in the area of mental health.
4. Investment Contract Date
Investment contract date: March 3, 2023
EPS Holdings, Inc.
EPSHD is a healthcare solutions provider that has been handling all processes from drug
discovery and development to sales, marketing, consulting, and various other solutions since its
founding as a pioneer CRO in Japan in 1991. EPSHD broadening its businesses as well by also
engaging in initiatives to bring new value to pharmaceutical and medical device companies,
hospitals, clinics, and academia through efforts that include expansion in China and the rest of Asia,
big data and AI, and regenerative medicine. In 2021, EPSHD launched an innovative medicine
business and started services to support the clinical development of seeds originating at academic
institutions and domestic and global biotech ventures and to support marketing in and outsideJapan.
Logos Science Co., Ltd.
Founded in 2022, Logos Science is engaged in the business of developing apps/systems forstress-related disorders and mental health care. It aims to achieve wellbeing through the science oflanguage and contributes to the realization of a society free of suffering by helping to solve social
issues through its application/system development business for stress-related diseases and mental
health care.
*1: Contract Research Organization (CRO)*2: Site Management Organization (SMO)*3: Contract Sales Organization (CSO)*4: Dr. App® is a registered trademark of Logos Science Co., Ltd.
Contact:
EPS Holdings, Inc.
Corporate Communications OfficeE-mail：pr@eps.co.jp
Logos Science Co., Ltd.
Public Relations
Shimokawa.
E-mail: info@logossjp.com
3